New data highlights a staggering disparity in insulin access: approximately 8.4 million people worldwide living with Type 1 diabetes require daily insulin injections for survival, yet a significant proportion lack adequate access to treatment. This insulin-dependent population faces disproportionate challenges in low- and middle-income countries, where supply chain limitations and affordability barriers restrict treatment options.
Insulin’s essential role in glucose regulation makes access failures particularly critical—without consistent therapy, Type 1 diabetes patients face life-threatening complications including diabetic ketoacidosis and long-term organ damage. The global distribution gaps reveal that despite over a century of pharmaceutical advancement, economic and logistical obstacles continue to prevent equitable access to this fundamental treatment. Addressing these disparities requires coordinated international efforts to strengthen supply chains, reduce manufacturing costs, and ensure affordable insulin availability across all regions.
Read the full article on GMJ Newsroom.
Was this article helpful?
